Éva Malpass

9 POSTS 0 COMMENTS

Review urges development of protocols to reduce hypersensitivity reactions after cyanoacrylate...

Cyanoacrylate
Despite being considered “generally safe”, cyanoacrylate can cause local reactions in up to 25% of patients, disproportionately affecting women, Asian race and thin patients...

Biolitec announces two new devices in the ELVeS radial portfolio

biolitec
Biolitec recently announced that it has extended its ELVeS Radial laser system for the minimally invasive laser treatment of insufficient veins by two further...

FLAME, FLASH and ongoing PEERLESS trials collect “compelling” data for FlowTriever...

Speaking on the FLAME, FLASH and PEERLESS trials that each collected data on the FlowTriever (Inari Medical) device for the treatment of pulmonary embolism...

JETi registry provides “remarkable results” for peripheral thrombectomy system

Presenting “remarkable results” from the JETi registry—a prospective, multicentre, observational study which collected real-world data on the safety, performance and clinical benefits of the...

Study finds anatomic positioning and physical activity type can cause device...

stent deformation
A recent multicentre, prospective study has found that stent deformations are greater in the common iliac vein with higher levels of hip flexion, as...

Analysis of varicose vein registry finds women benefit from endovenous ablation...

clottriever-VIVA-19
An evaluation of the Vascular Quality Initiative’s (VQI) Varicose Vein Registry (VVR) carried out by the Midwestern Vascular Surgical Society (MVSS) has found women...

Meta-analysis of PTS finds one in five risk of long-term symptoms...

DVT
A meta-analysis is first to report the pooled risk of post-thrombotic syndrome (PTS) after isolated distal deep vein thrombosis (DVT). Researchers revealed a one...

Boston Scientific announces investment to acquire majority stake of Acotec Scientific

Boston Scientific has announced that it will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares...

Real-world analysis confirms benefit of Xarelto in treating CAT as apixaban

reduced hospital time and costs Xarelto anticoagulant
Head-to-head observational analysis showed Xarelto as effective in treating cancer-associated thromboembolism (CAT) as apixaban. The Janssen Pharmaceutical Companies of Johnson & Johnson have announced observational...